Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

43.980
+0.0200.05%
Volume:1.78M
Turnover:77.34M
Market Cap:291.90B
PE:31.89
High:43.980
Open:43.900
Low:43.200
Close:43.960
52wk High:94.869
52wk Low:43.200
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.00
T/O Rate:0.69%
Dividend:0.23
Dividend Rate:0.53%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:3.87
PE(LYR):31.89
PS:7.97

Loading ...

Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials

MT Newswires Live
·
Jul 14

Hengrui Pharma's HRS-7058 Capsule Designated as Breakthrough Therapy

Stock News
·
Jul 13

Hengrui Pharma's FXI Antibody SHR-2004 Unveils Pivotal Phase III Data at ISTH 2026 LBA Session

Deep News
·
Jul 13

AH Share Premium and Deviation Rankings as of July 13th Close

Stock News
·
Jul 13

Hengrui Pharma's Key Drug Iohexol Injection Added to National Essential Medicines List

Stock News
·
Jul 10

AH Share Premium and Deviation Rankings for July 10

Stock News
·
Jul 10

Hengrui Pharma Receives FDA Complete Response Letter for Camrelizumab Injection Application

Stock News
·
Jul 10

Movement Alert|Hengrui Pharma Rises 3.08% in Regular Trading, UBS Reiterates Buy Rating on Positive Weight-Loss Drug Data

Market Focus
·
Jul 10

UBS Reiterates 'Buy' on Hengrui Pharma, Citing Positive Weight-Loss Drug Data and Attractive Valuation

Stock News
·
Jul 09

AH Share Premium and Deviation Data for July 8th

Stock News
·
Jul 08

Movement Alert|Hengrui Medicine Rises 3.6% in Regular Trading, Proprietary Anti-Tumor Drug SHR-4685 Approved for Clinical Trials

Market Focus
·
Jul 08

Are "Old Economy" Stocks Signaling a Market Shift?

Deep News
·
Jul 06

AH Share Premium and Deviation Data for July 6th

Stock News
·
Jul 06

Movement Alert|Hengrui Pharma Rises 4.01% in Regular Trading, Pharmaceutical Sector Rallies Amid Multiple Drug Approval Catalysts

Market Focus
·
Jul 06

AH Share Premium and Deviation Rankings for July 3rd

Stock News
·
Jul 03

Movement Alert|Hengrui Pharma Rises 3.2% in Regular Trading, Multiple New Drug Approvals and Priority Review Catalyze Gains

Market Focus
·
Jul 03

Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma

MT Newswires Live
·
Jul 03

Hengrui Pharma Reports Cumulative Share Buyback Totaling 13.47 Million A-Shares as of June 30

Stock News
·
Jul 02

Hengrui Pharma Gains Regulatory Nod for Clinical Trials of Three Drug Candidates

Stock News
·
Jul 02

HENGRUI PHARMA Keeps H-Share Capital Steady, Ups A-Share Treasury Stock via RMB 66.1 Million Buy-back in June

Bulletin Express
·
Jul 02